Related references
Note: Only part of the references are listed.Use of Apixaban in Atrial Fibrillation With Ritonavir-Boosted Antiretroviral Therapy: A Case Report
Veronica Lomakina et al.
JOURNAL OF PHARMACY PRACTICE (2023)
Effect of nirmatrelvir/ritonavir on calcineurin inhibitor levels: Early experience in four SARS-CoV-2 infected kidney transplant recipients
Aileen X. Wang et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants
Nicholas W. Lange et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Jennifer Hammond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients
David M. Salerno et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions
Catia Marzolini et al.
ANNALS OF INTERNAL MEDICINE (2022)
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment
Karthik Lingineni et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
Perrine Courlet et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect
Felix Stader et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Drug interactions: a review of the unseen danger of experimental COVID-19 therapies
Daryl Hodge et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
Robert Hermann et al.
CLINICAL PHARMACOKINETICS (2019)
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers
Hwa-Ping Feng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
No Clinically Relevant Interactions of St. John's Wort Extract Ze 117 Low in Hyperforin With Cytochrome P450 Enzymes and P-glycoprotein
Catherine Zahner et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2019)
Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report
Rita Godinho et al.
BMC NEPHROLOGY (2019)
Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update
Elise J. Smolders et al.
CLINICAL PHARMACOKINETICS (2019)
Ritonavir- or cobicistat-boosted antiretroviral therapy and direct oral anticoagulants: A case for apixaban
Sarah A. Nisly et al.
INTERNATIONAL JOURNAL OF STD & AIDS (2019)
Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates
Diane Ramsden et al.
DRUG METABOLISM AND DISPOSITION (2019)
Clinically relevant drug interactions with multikinase inhibitors: a review
Koen G. A. M. Hussaarts et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications
Felix Stader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions
Iria Bravo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites
Niloufar Marsousi et al.
CLINICAL PHARMACOKINETICS (2018)
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
Kay Seden et al.
PLOS ONE (2017)
Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV
Kimberly K. Scarsi et al.
DRUG SAFETY (2016)
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications
Catia Marzolini et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Twenty years of boosting antiretroviral agents: where are we today?
Marta Boffito et al.
AIDS (2015)
Drug Interactions Between Antiplatelet or Novel Oral Anticoagulant Medications and Antiretroviral Medications
Gregory Egan et al.
ANNALS OF PHARMACOTHERAPY (2014)
Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Wolfgang Mueck et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach
Marco Siccardi et al.
CLINICAL PHARMACOKINETICS (2013)
Concentration effect relationship of CYP3A inhibition by ritonavir in humans
Christine Eichbaum et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management
P. Saberi et al.
HIV MEDICINE (2013)
A Probable Interaction between Warfarin and the Antiretroviral TRIO Study Regimen
Michelle D Liedtke et al.
ANNALS OF PHARMACOTHERAPY (2012)
Determining the Time Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling Strategy
S. Katzenmaier et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir
Tuija H. Nieminen et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Drug-Drug Interaction in a Kidney Transplant Recipient Receiving HIV Salvage Therapy and Tacrolimus
Dominik Mertz et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2009)
Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment
Stefano Bonora et al.
CLINICAL INFECTIOUS DISEASES (2008)
Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
RE Aarnoutse et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Blood concentrations of everolimus are markedly increased by ketoconazole
JM Kovarik et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Sirolimus and ketoconazole co-prescription in renal transplant recipients
PP Thomas et al.
TRANSPLANTATION (2004)
Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients
M Vogel et al.
LIVER TRANSPLANTATION (2004)
Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors
CB Washington et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2003)
Population pharmacokinetics of long-term oral amiodarone therapy
PT Pollak et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Share Paper
